← Back to Discover
Sanofi
Period ended Sep 30, 2026 · Latest filing Nov 5, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Sep 30, 2026: $629,867,590
More quarters will appear as history becomes available.
Top holdings
Top 10 at Sep 30, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- MeiraGTx Holdings plc · COM · G59665102 · shares: $134,175,107
- Inhibrx Biosciences, Inc. · COM · 45720N103 · shares: $115,885,234
- Novavax · COM NEW · 670002401 · shares: $74,378,000
- Korsana Biosciences · COM · 23255M303 · shares: $63,808,352
- Odyssey Therapeutics Inc. · COMMON STOCK · 67613T104 · shares: $44,222,244
- AnaptysBio · COM · 032724106 · shares: $41,309,548
- Agomab Therapeutics NV · SPONSORED ADS · 00860C102 · shares: $30,892,366
- First Tracks Biotherapeutics Inc. · ORD SHS · 337185102 · shares: $29,128,738
- Electra Therapeutics Inc · COM · 284825106 · shares: $27,696,915
- Attovia Therapeutics Inc · COM · 04987L102 · shares: $18,560,135
Reported holdings
16 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| MeiraGTx Holdings plc | COM | G59665102 | — | 12,197,737 shares | $134,175,107 |
| Inhibrx Biosciences, Inc. | COM | 45720N103 | — | 1,157,926 shares | $115,885,234 |
| Novavax | COM NEW | 670002401 | — | 6,880,481 shares | $74,378,000 |
| Korsana Biosciences | COM | 23255M303 | — | 1,994,011 shares | $63,808,352 |
| Odyssey Therapeutics Inc. | COMMON STOCK | 67613T104 | — | 1,990,200 shares | $44,222,244 |
| AnaptysBio | COM | 032724106 | — | 821,917 shares | $41,309,548 |
| Agomab Therapeutics NV | SPONSORED ADS | 00860C102 | — | 2,783,096 shares | $30,892,366 |
| First Tracks Biotherapeutics Inc. | ORD SHS | 337185102 | — | 821,917 shares | $29,128,738 |
| Electra Therapeutics Inc | COM | 284825106 | — | 2,461,948 shares | $27,696,915 |
| Attovia Therapeutics Inc | COM | 04987L102 | — | 1,082,855 shares | $18,560,135 |
| Latigo Biotherapeutics Inc | COM | 517954103 | — | 672,778 shares | $11,235,393 |
| Immuneering Corp | CLASS A COM | 45254E107 | — | 2,708,559 shares | $11,091,549 |
| MapLight Therapeutics Inc. | COM | 56565P103 | — | 912,041 shares | $9,293,698 |
| Scribe Therapeutics | COM | 811033109 | — | 500,000 shares | $9,202,500 |
| SAB BIOTHERAPEUTICS INC | COM NEW | 78397T202 | — | 2,198,500 shares | $6,969,245 |
| Q32 Bio Inc. | COM | 746964105 | — | 244,083 shares | $2,018,566 |